AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9175942 — intervention group
Group type: EXPERIMENTAL
Intervention: Score developed based on multiple regression analysis including birthweight, Apgar score at 5 minutes, base excess at admission, severity of respiratory distress syndrome, and artificial ventilation.
Number of subjects: 572
Study 9175942 — intervention group
Group type: EXPERIMENTAL
Intervention: Score validation cohort (cutoff of 21).
Number of subjects: 572
Study 9175942 — intervention group
Group type: COMPARATOR
Intervention: Comparison of risk adjusted mortality between two eras (1978-87 and 1988-91).
Number of subjects: 572
Study 1539788 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach sciatic nerve block (group A)
Number of subjects: 40
Study 1539788 — intervention group
Group type: COMPARATOR
Intervention: Popliteal fossa approach sciatic nerve block (group B)
Number of subjects: 40
Study 2951808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (200, 1,000, and 2,000 micrograms)
Number of subjects: 12
Study 2951808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28953076 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesair Balloon placement
Number of subjects: 221
Study 28953076 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham-controlled)
Number of subjects: 221
Study 26405233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow-derived cells (BMC)
Number of subjects: 100
Study 26405233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25350669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 50,000 IU once a week for 2 months and then monthly for 10 months
Number of subjects: 192
Study 25350669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 22406101 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Activation
Number of subjects: 200
Study 22406101 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (Control)
Number of subjects: 200
Study 20513174 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Chain Triglyceride (MCT) oil
Number of subjects: 90
Study 20513174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolving thin film strips
Number of subjects: 90
Study 20513174 — intervention group
Group type: COMPARATOR
Intervention: Gelatin capsules
Number of subjects: 90
Study 18794541 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT arm; fluorouracil [FU] 400 mg/m(2) IV once daily plus dl‐leucovorin 200 mg/m(2) for 5 days or FU 370 mg/m(2) plus l‐leucovorin 100 mg/m(2) IV for 5 days for six cycles at 28-day intervals)
Number of subjects: 278
Study 18794541 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT arm)
Number of subjects: 278
Study 18794541 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (S arm)
Number of subjects: 278
Study 16101723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 115
Study 16101723 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 115
Study 12434284 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of fruits and vegetables (highest vs lowest quintile)
Number of subjects: 27111
Study 12434284 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of specific groups of fruits and vegetables (berries and cruciferous vegetables)
Number of subjects: 27111
Study 12434284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intakes of alpha-carotene, beta-carotene, lycopene, lutein/zeaxanthin, beta-cryptoxanthin, vitamins A, E, and C, and folate
Number of subjects: 27111
Study 9683312 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled onset-extended release (COER)-verapamil (180 mg/d)
Number of subjects: 15000
Study 9683312 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) including hydrochlorothiazide (HCTZ) or atenolol
Number of subjects: 15000
Study 7655108 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol in ointment for 12 weeks
Number of subjects: 2
Study 7655108 — intervention group
Group type: COMPARATOR
Intervention: Ointment base only for 12 weeks
Number of subjects: 2
Study 2832568 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 13
Study 2832568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula husk
Number of subjects: 13
Study 2832568 — intervention group
Group type: COMPARATOR
Intervention: Liquid control meals
Number of subjects: 13
Study 30341006 — intervention group
Group type: COMPARATOR
Intervention: Cligosiban 0.3-2,400 mg (aqueous solutions or dispersions)
Number of subjects: 34
Study 30341006 — intervention group
Group type: COMPARATOR
Intervention: Cligosiban 800 mg (capsules and aqueous dispersion)
Number of subjects: 34
Study 30341006 — intervention group
Group type: COMPARATOR
Intervention: Cligosiban 1,600 mg (caplets and aqueous dispersion)
Number of subjects: 34
Study 30341006 — intervention group
Group type: COMPARATOR
Intervention: Cligosiban (various doses)
Number of subjects: 34
Study 30341006 — intervention group
Group type: COMPARATOR
Intervention: Cligosiban (800 mg)
Number of subjects: 34
Study 28375108 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingocap
Number of subjects: 65
Study 28375108 — intervention group
Group type: COMPARATOR
Intervention: Pyridoxine
Number of subjects: 65
Study 24714097 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPJ-based emollients
Number of subjects: 0
Study 24714097 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum-based emollients
Number of subjects: 0
Study 23638997 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 32
Study 23638997 — intervention group
Group type: COMPARATOR
Intervention: Vaseline (placebo)
Number of subjects: 32
Study 21780209 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich lychee fruit extract (FRLFE)
Number of subjects: 20
Study 21780209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19455053 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CP-532,623
Number of subjects: 0
Study 19455053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CP-532,623
Number of subjects: 0
Study 19455053 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib
Number of subjects: 0
Study 19455053 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-532,623
Number of subjects: 0
Study 19455053 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib and CP-532,623
Number of subjects: 0
Study 16434254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 36
Study 16434254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15272911 — intervention group
Group type: EXPERIMENTAL
Intervention: TT subjects during sodium restriction
Number of subjects: 44
Study 15272911 — intervention group
Group type: COMPARATOR
Intervention: C allele subjects
Number of subjects: 44
Study 11379808 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP (200 to 800 microg daily)
Number of subjects: 473
Study 11379808 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP (400 to 1600 microg daily)
Number of subjects: 473
Study 11379808 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP
Number of subjects: 473
Study 11379808 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP
Number of subjects: 473
Study 9216523 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 12
Study 9216523 — intervention group
Group type: COMPARATOR
Intervention: White soft paraffin
Number of subjects: 12
Study 9216523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide production
Number of subjects: 12
Study 9216523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound scan
Number of subjects: 12
Study 8481621 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 10
Study 8481621 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 10
Study 8481621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8481621 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg and 400 mg)
Number of subjects: 10
Study 4018941 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 0
Study 4018941 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide
Number of subjects: 0
Study 4018941 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 0
Study 4018941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diuresis
Number of subjects: 0
Study 30964889 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq analysis of male and female progeny plants
Number of subjects: 140
Study 30964889 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq analysis of 39 sex-chromosomal genes
Number of subjects: 140
Study 30964889 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis using a large-scale population (>1400) and over 100 spinach germplasm accessions and cultivars
Number of subjects: 140
Study 30964889 — intervention group
Group type: EXPERIMENTAL
Intervention: Synonymous substitution rates of the MSY genes and X homologues
Number of subjects: 140
Study 30964889 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative analysis with S. tetrandra
Number of subjects: 140
Study 29195133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 34
Study 29195133 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA fish oil (high-DHA-FO)
Number of subjects: 34
Study 29195133 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 34
Study 27051055 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin (50 mg/m2) for 60 minutes after complete cytoreduction.
Number of subjects: 19
Study 27051055 — intervention group
Group type: COMPARATOR
Intervention: Standard first-line treatment (6 conventional cycles of chemotherapy after CS with HIPEC).
Number of subjects: 19
Study 24571858 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion (median 3 units, interquartile range 2-5)
Number of subjects: 213
Study 24571858 — intervention group
Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 213
Study 22614720 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee with 67 mg caffeine
Number of subjects: 21
Study 22614720 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee with 134 mg caffeine
Number of subjects: 21
Study 22614720 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (130 mg caffeine)
Number of subjects: 21
Study 22614720 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control capsule
Number of subjects: 21
Study 20135748 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bio-three: Bacillus mesentericus, Enterococcus faecalis, Clostridium butyricum)
Number of subjects: 304
Study 20135748 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bio-three)
Number of subjects: 304
Study 20135748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 19226018 — intervention group
Group type: EXPERIMENTAL
Intervention: Morcellized bone grafting
Number of subjects: 29
Study 17845947 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys distributed at work
Number of subjects: 1954
Study 17845947 — intervention group
Group type: COMPARATOR
Intervention: Surveys mailed directly to homes
Number of subjects: 1954
Study 15025848 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of r-hCG (0.5 mL of 250 microg/0.5 mL)
Number of subjects: 0
Study 15025848 — intervention group
Group type: COMPARATOR
Intervention: Freeze-dried formulation of r-hCG (1.0 mL of 250 microg/mL)
Number of subjects: 0
Study 15025848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 0
Study 10990077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin (5 mg daily)
Number of subjects: 82
Study 10990077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 9365349 — intervention group
Group type: EXPERIMENTAL
Intervention: Active magnetic device (300 to 500 Gauss)
Number of subjects: 50
Study 9365349 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 50
Study 1315383 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2766
Number of subjects: 18
Study 1315383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3966831 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam (MOX)
Number of subjects: 94
Study 3966831 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin and Clindamycin (TM/C)
Number of subjects: 94
Study 3966831 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K treatment
Number of subjects: 94
Study 31065731 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (75–125 mg)
Number of subjects: 103
Study 31065731 — intervention group
Group type: COMPARATOR
Intervention: Placebo/control (0–40 mg)
Number of subjects: 103
Study 27783849 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide cocktail therapy (KIF20A-derived peptide vaccine combined with antiangiogenic cancer vaccines targeting VEGFR1 and VEGFR2) plus gemcitabine
Number of subjects: 68
Study 25732978 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS‐Medtronic) calibrated by the glucometer Calla, Wellion, Austria
Number of subjects: 12
Study 23540891 — intervention group
Group type: EXPERIMENTAL
Intervention: SB203580
Number of subjects: 23
Study 23540891 — intervention group
Group type: COMPARATOR
Intervention: DMSO
Number of subjects: 23
Study 23540891 — intervention group
Group type: COMPARATOR
Intervention: SAH
Number of subjects: 23
Study 21536936 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 850
Study 21536936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study 19239406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma (FFP)
Number of subjects: 12
Study 19239406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 12
Study 19239406 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation factors VIII (FVIII)
Number of subjects: 12
Study 19239406 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation factors XIII (FXIII)
Number of subjects: 12
Study 19239406 — intervention group
Group type: COMPARATOR
Intervention: 40 vol% gelatin dilution
Number of subjects: 12
Study 16175627 — intervention group
Group type: EXPERIMENTAL
Intervention: modafinil
Number of subjects: 14
Study 16175627 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 12899793 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIFN-gamma (1 MU intramuscularly daily for the first three months and 1 MU every other day for the following six months)
Number of subjects: 289
Study 12899793 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIFN-gamma
Number of subjects: 289
Study 10709154 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg risedronate
Number of subjects: 23
Study 10709154 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg risedronate
Number of subjects: 23
Study 10709154 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg risedronate
Number of subjects: 23
Study 9199591 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate
Number of subjects: 30
Study 9199591 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo mouthrinse)
Number of subjects: 30
Study 1491149 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared emission detection tympanic thermometers with ear tug technique
Number of subjects: 40
Study 1491149 — intervention group
Group type: COMPARATOR
Intervention: Infrared emission detection tympanic thermometers without ear tug technique
Number of subjects: 40
Study 3903647 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 91
Study 3903647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 30953319 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1690 600 mg once daily for 12 weeks
Number of subjects: 0
Study 30953319 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1690 (various doses from 20 mg to 1500 mg, including multiple daily doses of 300-1000 mg)
Number of subjects: 0
Study 30953319 — intervention group
Group type: COMPARATOR
Intervention: GLPG1690 600 mg
Number of subjects: 0
Study 29990653 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight
Number of subjects: 364
Study 29990653 — intervention group
Group type: COMPARATOR
Intervention: Project Health
Number of subjects: 364
Study 27050139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular sprifermin (300 μg)
Number of subjects: 55
Study 27050139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular sprifermin (single and multiple doses)
Number of subjects: 55
Study 27050139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 27050139 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular sprifermin and Placebo
Number of subjects: 55
Study 27050139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular sprifermin
Number of subjects: 55
Study 25048494 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tacrolimus (extended-release), converted from twice-daily tacrolimus at 1 month post-transplantation
Number of subjects: 60
Study 25048494 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily tacrolimus
Number of subjects: 60
Study 25048494 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tacrolimus
Number of subjects: 60
Study 22508830 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg plus entinostat 10 mg (EE)
Number of subjects: 132
Study 22508830 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib 150 mg plus placebo (EP)
Number of subjects: 132
Study 20181970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.5 mg/day
Number of subjects: 8556
Study 20181970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.25 mg/day
Number of subjects: 8556
Study 20181970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8556
Study 18042015 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step PCN tube
Number of subjects: 65
Study 18042015 — intervention group
Group type: COMPARATOR
Intervention: Multistep fascial dilator system
Number of subjects: 65
Study 15643700 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-PRP-T (Hib conjugate) vaccine
Number of subjects: 55073
Study 15643700 — intervention group
Group type: COMPARATOR
Intervention: DTP (control group)
Number of subjects: 55073
Study 11115824 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexipafant (100 mg/24 hours intravenously for seven days)
Number of subjects: 290
Study 11115824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 11115824 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexipafant
Number of subjects: 290
Study 9531201 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (suture repair of disrupted ligaments within 72 hours, followed by immobilization in a below-the-knee plaster cast for 6 weeks)
Number of subjects: 146
Study 9531201 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment (ankle orthosis for 6 weeks)
Number of subjects: 146
Study 9531201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study 8010422 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB)
Number of subjects: 250
Study 8010422 — intervention group
Group type: COMPARATOR
Intervention: Dorsal penile nerve block (DPNB) with additional ventral injection
Number of subjects: 250
Study 2499490 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial glypressin (1 mg)
Number of subjects: 27
Study 2499490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glypressin (1 mg)
Number of subjects: 27
Study 2499490 — intervention group
Group type: COMPARATOR
Intervention: Endobronchial glypressin
Number of subjects: 27
Study 2499490 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glypressin
Number of subjects: 27
Study 4947493 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid prophylaxis for 1 year
Number of subjects: 0
Study 4947493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31512906 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat exposures (CEs) primed by presenting CE questions before MH instruments
Number of subjects: 464
Study 31512906 — intervention group
Group type: COMPARATOR
Intervention: Combat exposures (CEs) primed by presenting CE questions after MH instruments
Number of subjects: 464
Study 31738448 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% (5 mL)
Number of subjects: 20
Study 31738448 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% (10 mL)
Number of subjects: 20
Study 31242925 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated algorithms (Naïve Bayes Classifier, King‐Lu, InSilicoVA, InSilicoVA‐NT, InterVA‐4, SmartVA)
Number of subjects: 9374
Study 31242925 — intervention group
Group type: COMPARATOR
Intervention: Physician assignment of cause of death
Number of subjects: 9374
Study 28576903 — intervention group
Group type: EXPERIMENTAL
Intervention: One Take Charge session
Number of subjects: 400
Study 28576903 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Take Charge sessions 6 weeks apart
Number of subjects: 400
Study 28576903 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 400
Study 24534012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary glycemic load
Number of subjects: 91
Study 24534012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary insulin load
Number of subjects: 91
Study 24534012 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced energy diet
Number of subjects: 91
Study 24534012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary glycemic index and macronutrient content
Number of subjects: 91